Table 3.
Results of the meta-analysis
| Follow-up | Evaluation tools | Studies | Patients (PRP/HA) | MD | 95% CI | P<0.05 | I2 |
|---|---|---|---|---|---|---|---|
| 3 months | WOMAC total score | 3 | 153/154 | −10.82 | −19.74 to −1.91 | Yes | 89% |
| WOMAC pain | 2 | 82/84 | −0.5 | −1.66 to 0.66 | No | 81% | |
| VAS | 2 | 78/79 | −0.98 | −2.55 to 0.59 | No | 95% | |
| EQ VAS | 2 | 144/139 | 5.91 | −1.51 to 13.34 | No | 79% | |
| 6 months | WOMAC total score | 5 | 290/289 | −14.18 | −26.12 to −2.23 | Yes | 95% |
| WOMAC pain | 4 | 219/219 | −2.0 | −3.60 to −0.39 | Yes | 90% | |
| VAS | 2 | 78/79 | −0.82 | −1.80 to 0.16 | No | 83% | |
| WOMAC function | 3 | 170/169 | −5.78 | −14.73 to 3.16 | No | 92% | |
| EQ VAS | 4 | 232/228 | 2.19 | −11.47 to 15.85 | No | 98% | |
| IKDC | 4 | 232/228 | 8.53 | 4.52 to 12.53 | Yes | 79% | |
| 12 months | WOMAC total score | 4 | 207/194 | −15.25 | −22.17 to −8.32 | Yes | 81% |
| WOMAC pain | 3 | 158/144 | −2.22 | −3.65 to −0.79 | Yes | 92% | |
| WOMAC function | 3 | 158/144 | −11.17 | −16.37 to −5.98 | Yes | 83% | |
| EQ VAS | 2 | 143/139 | −4.64 | −21.79 to 12.51 | No | 98% | |
| IKDC | 2 | 143/139 | 6.84 | −1.96 to 15.63 | No | 91% |
Abbreviations: CI, confidence interval; EQ VAS, EuroQol-visual analog scales; HA, hyaluronic acid; IKDC, Subjective International Knee Documentation Committee; MD, mean difference; PRP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.